Skip Navigation

Grants

..Perifosine And Bortezomib With Or Without Dexamethason

..Propargyl-10-Dezaaminopterin (Praletrexate) W/Vitamin

..Study Of Enzastaurin Vs Lomustine In The Treatment Of

..Study Of The Current Liquid And Commercial Liquid Form

041-03 Microarray Analysis Of Patients With Diffuse Larg

06-Don

111476: An Open, Single Arm Study to Assess the Clinical Activity of recMAGE-A3 + AS15

273-08-201

3129K2-1105-Ww

9090-06: Phase 2 Sta-9090 In Subjects With Stage Iiib Or Iv Non-Small Cell Lung Ca

A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Adjuvant Treatment of High-risk Primary Uterine Leiomyosarcoma

A Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

A Dose Escalation Safety and Pharmacokinetic Study of SAR103168

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor

A Double-Blind, Randomized, Placebo-Controlled Phase Iii

A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients with Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) treated with the EGFR-TKI, Erlotinib

Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) (ECO-1)

A Multicenter, Open-Labeled, Randomized, Phase II/III St

A Multi-Center, Prospective, Open-Labeled, CT To Assess

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study

A Multi-Institutional Phase I/II Study Of Revlimid-Lenal

A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100

An Intergroup Phase III Randomized Controlled Trial Comp

An International, Multicenter, Open-Label Study Of Vorin

An Open-Label, Dose Escalation, Phase 1 Study Of Mln4924

An Open-Label, Extended -Use Study Of Human Corticotropi

An Open Label, Multicenter Phase I Study To Evaluate Saf

An Open-label, Single-Arm, Phase 2 Study of Carfilzomib Maintenance Therapy

An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

An Open-Label Extended Use Study of Oral CEP-70

An Open-Label Phase I/II Study of TAK-700 in Combination with Docetaxel and Prednisone

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

An Open Label Treatment Extension Study of AMG 706

A Phase 1, Open-Label, Dose-Escalation, Multidose Study

A Phase 1, Open Label Study Of Pralatrexate W/Vitamin B1

A Phase 1/2, Multi-Center, Blinded, Randomized, Controll

A Phase 1/2 Multicenter, Randomized, Open-Label Dose Escalation Study To Determine

A Phase 1/2 Study Of Array-520 In Pts W/Advanced Myeloid

A Phase 1/2 Study Of R1507 In Combination W/Letrozole Fo

A Phase 1-B, Multicenter, Open-Label, Dose-Escalation St

A Phase 1 Open Label, Safety, Pharmacokinetic And Pharma

A Phase 2 Study of AZD6244 in Biliary Cancers

A Phase 2 Study of AZD6244 in Hepatocellular Carcinoma

A Phase 4 Study Of The Pharmacokinetics Of Oral Posacona

A Phase I/Iia Study Evaluating The Safety, Pharmokinetic

A Phase I/Ii Open-Label Study To Evaluate The Safety, Ph

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

A Phase I Dose Escalation Study To Evaluate Maximun Tole

A Phase Ii, Multicenter, Open-Label Trial Evaluating The

A Phase II, Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone

A Phase Ii/Iii Randomized Study Of Cdx-110 with Radiation A

A Phase III, Randomized Double Blind, Placebo-Controlled

A Phase Iii Multi-Institutional Immunization With Gp 10

A Phase Iii Randomized, Double-Blind, Placebo-Controlled

A Phase Iii Randomized, Double-Blind, Placebo-Controlled

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat

A Phase III randomized trial of adjuvant chemotherapy with or without Bevacizumab

A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab

A Phase III Trial of Cisplatin plus Paclitaxel

A Phase III Trial of Pelvic Radiation Therapy

A Phase II Multicenter, Randomized, Controlled, Open-Label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263

A Phase II Open-Label, Two Arm Trial To Evaluate The Eff

A Phase II Randomized, Placebo-Controlled, Double-Blind

A Phase Ii Study Of Oral Lbh589 In Adult Pts W/Refractor

A Phase II Study Of Single Agent Clofarabine In Previous

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131

A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas

A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

A Phase II Trial Of Pf-00299804 Vs Erlotinib For The Tre

A Phase II Trial Of R1507, A Recombinant Human Monoclonal Antibody

A phase II trial of temsirolimus and bevacizumab

A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001

A Pilot Phase II Study of Immunotherapy for the Treatment of AML, ALL, BP CML, and MDS

A Pivotal Phase Ii Trial Of Ponatinib (Ap24534) In Patients With Refractory Chron

A Prospective Randomized Double-Blind

A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice

A Randomized, Double-Blind, Multicenter Study Comparing Mdx 010 Monotherapy, Mdx 010 in Combination with a Melanoma Pept

A Randomized, Double-blind, Phase 3 Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naive...

A Randomized, Double-Blind, Placebo, Controlled Study To

A Randomized, Double-Blind Study To Determine The Effect

A Randomized, Multicenter, Phase Iii Open-Label Study Of The Efficacy And Safety

A Randomized, Open-Label, Multi-Centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of AZD 1152

A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion

A Randomized Phase 2 Open-Label Study of IMC-A12

A Randomized Phase 2 Study Of Tnferade With 5Fu And Radi

A Randomized Phase 3 Clinical Trial to Evaluate the Efficiency and Safety of Treatment with OncoVEX(GM-CSF)

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy

A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine

A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed

A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel

A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy

A Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-1R MoAB IMC-A12 for Patients with Extensive Stage Small Cell Lung Cancer

A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel

A Randomized Phase II Study of Oral Sapacitabine

A Randomized Phase II Trial of Azacitidine

A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (TITAN)

Arsenic-Induced Apoptosis In Myeloma

Assessing Cost Effectiveness Of Zevalin In The Management Of Non Hodgkin Lymphoma

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

A Study Of The Comparitive Activity And Potential Mechan

A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation

A Study Of The Pattern Of Expression Of Alpha-Folate Receptors...

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Atlanta Clinical and Translational Science Institute

A Trial Of Tandem Autologous Stem Cell Transplants +/- P

Autologous Vs Non-Myeloablative Hemapoietic Cell Transplant

Basic Transcription Factor Klf5 As A Key Regulator Of Pr

Bay43-9006/14295 Phase Iii Sorafenib

Besct (Biology, Education, Screening, Chemoprevention Tre

BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Biomarker-Based Approaches Of Targeted Therapy For Lung

BMT CTN 0803

BRE07-126: A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer

BT975: A Phase I/IIa, Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose

Building A Grid-Enabled Registry Resource For Comprehensive Cancer Research In Ga

C16001 Phase I Study Of Mln9708 In Adult Patients W/ Advanced Nonhematologic Malig

Ca184045: A Multicenter Treatment Protocol For Expanded Access Use Of Ipilimumab

Ca-Alt-836-02-10

Carpenter Fellowship Research Agreement

CD28-mediated regulation of multiple myeloma cell proliferation and survival

Chemoprevention of the Head and Neck Cancer with ZD1839

CHFR Methylation as Novel Predictor for Chemotherapy Response in NSCLC

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Clbh589Dus71: A Phase II, Multi-Center, Single Arm, Open Label Study Of Panobinost

Clinical Database For Bone Marrow And Peripheral Blood Stem Cell Transplant Outcom

Coe-03: Predicting Response And Toxicity In Patients Receiving Lonafarnib For Brea

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

Combination Proteasome Inhibition And Farnesyl Transfera

Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation

Comparison of Dendritic Cell Content and T-Cell Phenotype

Confocal Imaging Of Mitotic Biomarkers After Treatment W

Connect Registry

Control Of Lung Cancer Invasion And Metastasis By Vimentin

Control Of Lung Cancer Invasion By LKB1

Crad001Nus65:An Open-Label, Single-Arm Phase Ii Study Of Everolimus (Rad001) In Pa

CSOM230CUS18T: A 3-Arm Randomized Phase Ii Trial Evaluating Single Agent And Combi

Ctki258A2204 - A Phase Ii, Multi-Center, Non-Randomized, Open-Label Study Of Tki25

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies

Determination Of The Efficiacy Of Dual Targeting Anti-Eg

Development Of A Murine Mage-A3 Vaccine Using An Attenuated Listeria Monocytogenes

Development of a Novel Multi-Biomarker System

Development Of A Novel Multi-Biomarker System

Development Of A Novel Multi-Biomarker System

Direct Targeting Of Cancer Invasion And Metastasis Using Withania Root Extracts

Disease Progression In Patients With 8P Allelic Imbalanc

Distinguished Cancer Clinicians And Scientists Program

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

E1105 - A Randomized Phase III Double-Blind Placebo-Controlled Trial of 1st-line Chemotherapy and Trastuzumab Bevacizumab

E1208 A Phase III Randomized, Double-Blind Trial of Chemoembolization

E1608

E3205: Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma

E3A06: Randomized Phase III Trial Of Lenalidomide Versus Observation Alone In Pati

E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo

Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)

Eastern Cooperative Oncology Group

Effect Of FOXO1A Inactivation On P13K/AKT Inhibitor-Medi

Effects Of Extracorporeal Photopheresis In Immuno-Regula

Eliminating Disparities For Patients With Lymphoma

Emerge - A Phase II, Multi-Center, Single-Arm, Open-Label Study To Determine The E

Enhancing The Mtor-Targeting Cancer Therapy

Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

Evaluation Of The Efficacy Of BKM120 Alone And In Combination With RAD001 Against

Evaluation Of The Mechanism Of Romidepsin Induced Thromb

Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia

Fortis-M: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Oral T

Function And Mechanism Investigation Of Snorna U50 As A

GCC DCCS Program 2010

GCC DCCS Program 2010

GCC Distinguished Cancer Clinician And Scientists Program

Georgia Cancer Coalition Carpenter Award

Georgia Cancer Coalition-Distinguished Cancer Clinicians

Georgia Cancer Coaliton - Distinguished Clinician & Scientists

GOG 0212: A Randomized Phase III Trial Of Maintenance Chemotherapy

Gra 2010 Investment Program-Equipment Purchase

Human Corticotropin-Releasing Factor (hCRF) for Patients Requiring Chronic High-Doses of Dexamethasone

Identification and Characterization of Tumor Suppressor Genes in Prostate Cancer

Identifying High Risk Cells in Primary SCCHN to Predict Lymph Node Metastasis

IMCL CP12-0922

Imcl Cp20-0903 An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating Th

Imclone Cp12-0712: Ramucirumab/Qtc Interval (Ramalingam)

Immunologic And Virologic Effects Of Cmv Pp65 Specific Cytotoxic T Lymphocytes For

International Randomized Open-Label, Phase 3 Trial Of Pa

Investigating The Role Of LKB1 In Cancer Cell Polarity

In Vivo Evaluation Of Pasireotide And Everolimus In Thyroid Cancer Cell Lines And

Ipm3001: A Phase III, Multicenter, International, Double-Blind, Placebo-Controlled

I-Tm-601 In Adult Pat'S W/Recurrent High-Grade Glioma Re

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (CILAB)

LBH589D2308

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Leukemogenic Tyrosine Kinase Signaling

Long-Term Follow Up Study for AMD3100 Patients

Lung Cancer Mutation Consortium Trial

M10-943: A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-348 in Subjects with Advanced Hematologic Malignancies

Magrit 109493 A Double-Blind, Randomized, Placebo-Controlled Phase Iii Study To As

Mechanisms Of Metastasis: Regulation Of Fak By The Tumor Suppressor Lkb1

MFG4809G:An Open-Label, Multicenter, Phase I Trial Of The Safety And Pharmacokinet

Ml25597 A Single-Arm, Open-Label, Expanded Access Study Of RO5185426

Mmrc Validation Core For Bayer Pi3Ki

Molecular Biology of Familial Myeloproliferative Disorders

Molecular Profiling Of E2197 FFPE Samples Using A Custom

Molecular Profiling Of FFPE Tumor Tissue From IBCSG Clinical Trials In Breast Canc

MPD-RD: Correlative Biomarker Study For MPD-RC Treatment Studies In The

MSKCC

Multi-Center, Open-Label Phase II Study Of Gx15-070Ms

Multicenter, Phase Ii Trial Of High-Dose Il-2 With Primi

Multiple Biomarker Imaging by Quantum Dots for Prediction Of HPV Associated Cancer

Multiple Myeloma 2007 Center Of The Year Award Grant Mmp

Nci 8271: Phase Ii Dasatinib For Adenoid (Saba)

NCI 8443

Nci 8511: Phase I/Ii Study Of Cetuximab With R04929097 In Colon Cancer

NCI 8539

NCI 8784

Networks Of Tissue Source Site (Tss) In Support Of The Cancer Genome Atlas (Tcga)

No25026 - Brim 3: A Randomized, Open-Label, Controlled, Multicenter, Phase Iii St

Nv20234 A Double-Blind, Randomized, Stratified, Multi-Ce

Open-Label, Dose-Escalation Phase 1/2 Study of the Oral Form of MLN9708, A Second-Generation Proteasome Inhibitor, Administered in Combo with Lenalidomide and Low-Dose Dexamethasone in Patients

Open Label, Single Arm Phase 2 Study Of Carflizomib In P

Open-Label Phase 1/2 Study of VELCADE (Bortezomib)

Overexpression Of Ubiguitin E3 Ligase

P05615: Pharmacokinetics and Safety of Solid Oral Posaconazole

p90RSK2-Stathmin signaling in metastatic human cancers

Pazopanib in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Pazopanib in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Phase 1/2 Open Label Trial Of Sutent & Aromasin In 1St L

Phase 1b Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Phase 1 Study Of Osi-906 In Combination With Pemetrexed In Advanced Solid Tumors

Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066

Phase 3 Study Of Proteinase 3 PR1 Peptide Mixed With Mon

Phase 3 Trial Of Bortezomib And Rituximab Vs. Rituximab

Phase I, Multicenter, Open-label, Dose-escalation, Multidose Study of MDX-1203

Phase I/2 Multicenter, Open Label Trial Of The Safety An

Phase I/II Study Of A Muti-Antigen Therapeutic Vaccine I

Phase I/II Study of hLL1 in Multiple Myeloma

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Phase I/Ii Study Of Liposomal Annamycin In Pts With Refr

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase Ib, Multicenter, Open-Label Dose-Escalation Study

Phase Ib Dose Escalation Study Of Bortezomib And Sunitin

Phase II, Multicenter, Simon Two-stage Study of R788 in Patients With Relapsed or Refractory T-Cell Lymphoma

Phase II Fludarabine, Cytoxan and FCCAM in Untreated B-Cell Chronic Lymphocytic Leukemia

Phase III, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066

Phase III Randomized, Multicenter Study Comparing G-Csf

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine

Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone

Phase Iii Trial Comparing Sirolimus/Tacrolimus

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane)

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Phase Ii Study Of Bortezomib Ps-341 For Patients W/Advan

Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (ACT III)

Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.

Phase II Study of Oral Panobinostat in Adult Patients With Relapsed / Refractory Classical Hodgkin's Lymphoma

Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia

Phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia.

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients

Phase II Study of Time of Administration of Plerixafor

Phase II Study To Evaluate Safety And Efficacy Of Weekly

Phase II Trial of Lapatinib in Combination With Everolimus

Phase II Trial of Pre-operative Docetaxel-Cytoxan (TC) in Patients with Hormone Receptor-Positive Cancers with Recurrance Scores greater than or equal to 25

Phase I Multicenter, Study Of The Safety And Tolerabili

Phase I Protocol Of Sf1126 In Pts With Relapsed Or Refra

Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601

Phase I Study of Perifosine and Sorafenib for Patients With Advanced Cancers

Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas

Preclinical Efficacy Of R1507 In Her2 Overexpressing Breast Cancer Models

Preclinical Evaluation Of Combination Therapy With Vorin

Prognostic and predictive gene sets in HER2-positive breast cancer

Pro-Invasive Signaling Of LDHA In Cancer

Pro-Metastatic Role Of P90RSK2 In Head And Neck Cancer

Pro-Oncogenic Role Of Lkb1 In Nsclc

Prospective, longitudinal, multi-center, descriptive registry of patients receiving therapy other than surgical resction alone for newly diagnosed head and neck carcinoma

Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma

Prospective Randomized Trial On Preventing Oral Carcinom

Proteasome Inhibitor Sensitivity In Multiple Myeloma

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

Px-171-003: Open-Label, Single-Arm, Phase 2 Study Of Car

Randomized, Double-Blind, Multicenter, Two-Stage Adaptive Phase III Study of Intravenous Administration of Reolysin

Randomized, Double-Blind, Placebo-Controlled Study of the JAK Inhibitor INCB018424 Tablets

Randomized, Open-label Study of Oral CEP-701

Randomized Phase II Study Of Bevacizumab/Tarceva And Tar

Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin)

Re-expression of ER in Triple Negative Breast Cancers

Role Of Adipocytokines, Leptin And Adiponectin In Breast Carcinogenesis

Role Of ATBF1 Inactivation In The Devleopment And Progression of Prostate Cancer

Role Of P90RSK2 In FGFR3-Induced Hematopoietic Transform

RSK2 Signaling In Fefr3 Expressing T(4:14) Multiple Mye

Rv-St-Pi-0558: Phase I Study Of Everolimus (Rad001) In Combination With Lenalidomi

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

Safety Study of Dasatinib With Bortezomib (Velcade) and Dexamethasone for Multiple Myeloma

SARC 009: A Phase II Trial of Dasatinib in Advanced Sarcomas

Second Primary Tumor Prevention with EGFR TKIs, COX-2 inhibitors Head & Neck Cancer

Separating Anti-Tumor And Gvhd Effect In Allogeneic T-Cells

Signaling and Targeting of FGFR1 Fusions in 8p11 Myeloproliferative Syndrome

SOM - Dept of Hematology and Oncology Internal Page Display Name

Spectra Optia Apheresis System

Spore In Head And Neck Cancer

Study Evaluating CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

Study Of Bevacizumab In Myelofibrosis (Mpd-Rc-103)

Study Of Bms-345825 Administered Orally At A Dose 50 Or

Study Of CEP-701 (MPD-RC 104)

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Study of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma

Study Of Sub Q Homoharringtonine (Dgx-635) In Patients W

Study to Assess the Effectiveness of RCHOP With or Without VELCADE

Subcontract For Additional Data Collection For Merck & Co. - Nci Protocol #7863

Synergistic Combinations Of Targeted Agents For Meyloma

Synta 9090-07 - A Phase 1, Pharmacokinetic Study Of Sta-9090 In Combination With D

Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil

Targeted Delivery Of A Novel Synthetic Curcumin Analog, EF24 To Glioblastoma And

Targeted Delivery Of Anticancer Drugs

Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy

Targeting CHFR Through Paep-Inhibition

Targeting Mtor And Ras Signaling Pathways For Lung Cance

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF

The OPAL study: A phase II study to evaluate the efficacy, safety, and tolerability of tosedostat

Therapeutic Opportunities In Multiple Myeloma

Therapeutic Opportunities In Multiple Myeloma

The Role Of Cox-2 In Perifosine-Induced Apoptosis

The Role Of Ep4 In Fibronectin-Induced Human Lung Cancer Cell Growth

The Warburg Effect: Tyrosine Kinase Signaling In Leukemia Cell Metabolism

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel

Towards identification of prognostic gene sets in breast cancer

Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer

Transcription-dependent and independent signaling of RSK2 in cancer

Trastuzumab With or Without Everolimus in Estrogen Receptor-Positive Metastatic Breast Cancer

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Trial Of Paclitaxel & Bevacizumab Vs Gemcitabine, Paclit

Trial To Evaluate Palifermin In The Reducation Of Acut

Trial To Evaluate The Safety, Immunogenicity And Clinica

Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Txa127-2009-001

Tyrosine Kinase Signaling In Leukemia Metabolism

Uark 2004-19 Randomized, Double-Blind Multicenter Phase

Use Of Education And Patient Support To Increase Minorit

Using Modified Donor Lymphocytes To Boost Immunity In Tr

Vanguard Trial of Investigational Therapeutics in Adjuvant Treatment of Lung Cancer (VITAL)

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

WCI 1590-08: Phase Ii Neoadjuvant Trial Of Sorafenib In Combination With Cisplatin

Wci 1761-09: Phase 1/2B Carboplatin/Cetuximab/Rad001

Wci1871-10 - Phase Ib/Ii Study Of Induction Chemotherapy With Xelox, Followed By RWci1871-10 - Phase Ib/Ii Study Of Induction Chemotherapy With Xelox, Followed By R

Xl184-205: A Phase 2 Non-Comparative Randomized Open-Label Study Of Multiple Regim

Xl228: A Phase 1 Dose Escalation Study Of The Safety, Pharamacokinetics, And